Dr. Ruth O’Regan explains how tumor profiling tests work to help doctors and patients understand a patient’s risk of recurrence. As a researcher who has worked on the Breast Cancer Index test, she describes how this test works to determine which patients benefit from an extended course of hormone therapy and which patients can safely stop treatment after 5 years. Two-time breast cancer survivor Michelle Beck explains how crucial tumor profiling tests are to help patients make the best treatment decisions for themselves.
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Dr. Ruth O’Regan is a medical oncologist at University of Rochester
Michelle Beck is a speaker, author, podcast host and two-time breast cancer survivor
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: www.komen.org/...
Link to Survey: susangkomen.ia...
Clinical Trial Finder: www.breastcanc...
Videos:
Breast Cancer Breakthroughs Episode 8: Navigating Breast Cancer Recurrence: • Breast Cancer Breakthr...
Under the Microscope: Breast cancer recurrence: When cancer comes back: • Breast cancer recurren...
Under the Microscope: Tumor profiling tests: Tools to predict risk of recurrence: • Tumor profiling tests:...
Resources:
Breast Cancer Recurrence: www.komen.org/...
Emerging Areas in Drug Therapies for Early Breast Cancer: www.komen.org/...
Fear of Breast Cancer Recurrence: www.komen.org/...
Негізгі бет Tailoring breast cancer treatment with tumor profiling tests
Пікірлер